AUL
VRTX icon

AlphaGrep UK Ltd’s Vertex Pharmaceuticals VRTX Stock Holding History

AlphaGrep UK Ltd’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$346K Buy
774
+14
+2% +$6.53K 0.1% 441
2025
Q4 		$345K Buy
+760
New +$328K 0.12% 356

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AlphaGrep UK Ltd's VRTX Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q1 2026, buying an estimated $6.53K and bringing the position to 774 shares worth $346K. The position accounts for 0.1% of the portfolio, ranked #441.

AlphaGrep UK Ltd first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,694 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • AlphaGrep UK Ltd held 774 shares of Vertex Pharmaceuticals worth $346K as of Q1 2026.
  • AlphaGrep UK Ltd bought 14 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.53K.
  • Vertex Pharmaceuticals made up 0.1% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #441 holding.
  • AlphaGrep UK Ltd first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,694 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.